Jennison Associates LLC Bei Gene, Ltd. Transaction History

Jennison Associates LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 09, 2021	SELL	$249.6 - $403.14 $6.8 Million - $11 Million	-27,230 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$292.75 - $367.01 $2.09 Million - $2.62 Million	7,131 Added 35.48%	27,230 $9.35 Million
Q1 2021 May 11, 2021	BUY	$260.64 - $382.12 $3.31 Million - $4.86 Million	12,708 Added 171.94%	20,099 $7 Million
Q4 2020 Feb 05, 2021	BUY	$221.31 - $316.61 $451,693 - $646,201	2,041 Added 38.15%	7,391 $1.91 Million
Q3 2020 Nov 04, 2020	BUY	$189.18 - $286.44 $93,076 - $140,928	492 Added 10.13%	5,350 $1.53 Million
Q2 2020 Aug 06, 2020	BUY	$123.9 - $195.41 $324,246 - $511,387	2,617 Added 116.78%	4,858 $915,000
Q1 2020 May 06, 2020	BUY	$121.84 - $173.19 $4,264 - $6,061	35 Added 1.59%	2,241 $276,000
Q4 2019 Feb 07, 2020	SELL	$115.78 - $208.34 $267,104 - $480,640	-2,307 Reduced 51.12%	2,206 $366,000
Q4 2018 Feb 06, 2019	BUY	$107.01 - $175.15 $9,202 - $15,062	86 Added 1.94%	4,513 $633,000
Q3 2018 Nov 08, 2018	BUY	$152.62 - $189.66 $6,562 - $8,155	43 Added 0.98%	4,427 $762,000
Q2 2018 Aug 02, 2018	BUY	$152.5 - $216.77 $668,560 - $950,319	4,384 New	4,384 $674,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.